Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic

Abstract

Background: Therapeutic failure with antiretroviral therapy (ART) is a substantial issue where viral rebound, viral resistance and drug-related toxicity remain serious concerns. Drug exposure-response relationships have been described for the protease inhibitors, pharmacokinetic variability is substantial for this class of drugs and drug interactions can also alter ART exposure. Given this background we established a therapeutic drug monitoring (TDM) service to monitor atazanavir (ATV) plasma concentrations early after the therapy was made available to treatment-experienced people infected with HIV who were managed in a clinical setting.

Methods: This was a prospective observational study which evaluated plasma samples from 110 highly treatment-experienced people with HIV using TDM and applied pharmacokinetic analysis over a five month period.

Results: ATV trough concentrations exhibited substantial intersubject variability (<25-2108 microg l(-1)). A substantial number of subjects (50%,13/26) who received ATV400 mg daily had low exposure to ATV. Serum bilirubin concentrations correlated significantly with higher ATV trough concentrations (rho = 0.803; P < 0.001) and 55% (29/53) of subjects who received ATV300/100 mg RTV daily had plasma concentrations above a proposed target concentration associated with elevated bilirubin concentrations. This study confirmed low ATV exposure in eight subjects with HIV receiving ATV 400 mg daily. Reasons for low ATV exposure in this cohort include administration of interacting drugs, including a possible interaction with ritonavir, fluticasone and ATV, impaired ATV absorption secondary to suspected achlorhydria and potential interactions with colchicine and nandrolone. Viral load remained undetectable in most of these subjects with low ATV exposure.

Conclusions: TDM and targeted pharmacokinetic studies should be viewed as fundamental tools in the development and clinical application of ART, to improve pharmacotherapy for people with HIV.

Figure 1

Distribution of observed trough ATV plasma concentrations in 92 people with HIV receiving ATV300/RTV100 mg daily and 26 people receiving ATV 400 mg daily (MEC is the minimum effective concentration required to suppress viral replication [5])

Figure 2

Spearman correlation between serum bilirubin and observed ATV trough plasma concentrations for people receiving 300 ATV/RTV 100 mg daily. Horizontal dashed line represents normal serum billirubin target of 18 µmol l⁻¹. Vertical dotted line (500 µg l⁻¹) is the suggested target above which the probability of serum bilirubin elevation >43 µmol l⁻¹ is likely [5]. Solid line is the regression line

Figure 3

Observed ATV concentration–time profiles in 8 people with HIV receiving 400 mg daily who had undetectable trough plasma concentrations (MEC is the minimum effective concentration required to suppress viral replication [5])

Figure 4

Concentration–time profile in a person with HIV receiving boosted ATV demonstrating a dual interaction between RTV, fluticasone and ATV. 400/100 + fluticasone (•), HIV pop 300/100 (), 400/100 + fluticasone + cola drink (▾), 400/100 − fluticasone (▪)